These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. Arriola E; García Gómez R; Diz P; Majem M; Martínez Aguillo M; Valdivia J; Paredes A; Sánchez-Torres JM; Peralta Muñoz S; Barneto I; Gutierrez V; Andrade Santiago JM; Aparisi F; Isla D; Ponce S; Vicente Baz D; Artal A; Amador M; Provencio M BMC Cancer; 2018 Jan; 18(1):106. PubMed ID: 29382302 [TBL] [Abstract][Full Text] [Related]
63. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples. Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838 [TBL] [Abstract][Full Text] [Related]
64. Detection of EGFR somatic mutations in non-small cell lung cancer (NSCLC) using a novel mutant-enriched liquidchip (MEL) technology. Zhang L; Yang H; Zhao Y; Liu W; Wu S; He J; Luo X; Zhu Z; Xu J; Zhou Q; Ren-Heidenreich L Curr Drug Metab; 2012 Sep; 13(7):1007-11. PubMed ID: 22591345 [TBL] [Abstract][Full Text] [Related]
65. Detection of Rare Mutations in EGFR-ARMS-PCR-Negative Lung Adenocarcinoma by Sanger Sequencing. Liang C; Wu Z; Gan X; Liu Y; You Y; Liu C; Zhou C; Liang Y; Mo H; Chen AM; Zhang J Yonsei Med J; 2018 Jan; 59(1):13-19. PubMed ID: 29214771 [TBL] [Abstract][Full Text] [Related]
66. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Rosell R; Dafni U; Felip E; Curioni-Fontecedro A; Gautschi O; Peters S; Massutí B; Palmero R; Aix SP; Carcereny E; Früh M; Pless M; Popat S; Kotsakis A; Cuffe S; Bidoli P; Favaretto A; Froesch P; Reguart N; Puente J; Coate L; Barlesi F; Rauch D; Thomas M; Camps C; Gómez-Codina J; Majem M; Porta R; Shah R; Hanrahan E; Kammler R; Ruepp B; Rabaglio M; Kassapian M; Karachaliou N; Tam R; Shames DS; Molina-Vila MA; Stahel RA; Lancet Respir Med; 2017 May; 5(5):435-444. PubMed ID: 28408243 [TBL] [Abstract][Full Text] [Related]
67. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. Shaw AT; Yeap BY; Mino-Kenudson M; Digumarthy SR; Costa DB; Heist RS; Solomon B; Stubbs H; Admane S; McDermott U; Settleman J; Kobayashi S; Mark EJ; Rodig SJ; Chirieac LR; Kwak EL; Lynch TJ; Iafrate AJ J Clin Oncol; 2009 Sep; 27(26):4247-53. PubMed ID: 19667264 [TBL] [Abstract][Full Text] [Related]
68. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression. Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765 [TBL] [Abstract][Full Text] [Related]
69. Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision. Sousa AC; Silveira C; Janeiro A; Malveiro S; Oliveira AR; Felizardo M; Nogueira F; Teixeira E; Martins J; Carmo-Fonseca M Lung Cancer; 2020 Jan; 139():35-40. PubMed ID: 31715539 [TBL] [Abstract][Full Text] [Related]
70. Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib. Winther-Larsen A; Nissen PH; Jakobsen KR; Demuth C; Sorensen BS; Meldgaard P Lung Cancer; 2015 Nov; 90(2):314-20. PubMed ID: 26386832 [TBL] [Abstract][Full Text] [Related]
71. Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment. Marchetti A; Del Grammastro M; Felicioni L; Malatesta S; Filice G; Centi I; De Pas T; Santoro A; Chella A; Brandes AA; Venturino P; Cuccurullo F; Crinò L; Buttitta F PLoS One; 2014; 9(8):e103883. PubMed ID: 25137181 [TBL] [Abstract][Full Text] [Related]
72. Tissue and Plasma-Based Highly Sensitive Blocker Displacement Amplicon Nanopore Sequencing for EGFR Mutations in Lung Cancer. Akkhasutthikun P; Kaewsapsak P; Nimsamer P; Klomkliew P; Visedthorn S; Chanchaem P; Teerapakpinyo C; Payungporn S; Luangdilok S Cancer Res Treat; 2024 Apr; 56(2):455-463. PubMed ID: 37986562 [TBL] [Abstract][Full Text] [Related]
73. The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable Szpechcinski A; Moes-Sosnowska J; Skronska P; Lechowicz U; Pelc M; Szolkowska M; Rudzinski P; Wojda E; Maszkowska-Kopij K; Langfort R; Orlowski T; Sliwinski P; Polaczek M; Chorostowska-Wynimko J Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063150 [TBL] [Abstract][Full Text] [Related]
74. Detection of EGFR mutations in liquid biopsy samples using allele-specific quantitative PCR: A comparative real-world evaluation of two popular diagnostic systems. Szpechcinski A; Bryl M; Wojcik P; Czyzewicz G; Wojda E; Rudzinski P; Duk K; Moes-Sosnowska J; Maszkowska-Kopij K; Langfort R; Barinow-Wojewodzki A; Chorostowska-Wynimko J Adv Med Sci; 2021 Sep; 66(2):336-342. PubMed ID: 34274564 [TBL] [Abstract][Full Text] [Related]
75. Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patients. Breitenbuecher F; Hoffarth S; Worm K; Cortes-Incio D; Gauler TC; Köhler J; Herold T; Schmid KW; Freitag L; Kasper S; Schuler M PLoS One; 2014; 9(1):e85350. PubMed ID: 24465542 [TBL] [Abstract][Full Text] [Related]
76. Clinical Validation of the Unparalleled Sensitivity of the Novel Allele-Discriminating Priming System Technology-Based EGFR Mutation Assay in Patients with Operable Non-Small Cell Lung Cancer. Park IH; Son DS; Choi YL; Choi JH; Park JE; Jeon YJ; Cho M; Kim HK; Choi YS; Shim YM; Kang JH; Park S; Lee J; Kim SH; Lee BC; Kim J Cancer Res Treat; 2024 Jan; 56(1):81-91. PubMed ID: 37340844 [TBL] [Abstract][Full Text] [Related]
77. Clinical utility of the Oncomine Dx Target Test multi-CDx system and the possibility of utilizing those original sequence data. Saito A; Terai H; Kim TJ; Emoto K; Kawano R; Nakamura K; Hayashi H; Takaoka H; Ogata A; Kinoshita K; Ito F; Shigematsu L; Okada M; Fukushima T; Mitsuishi A; Shinozaki T; Ohgino K; Ikemura S; Yasuda H; Kawada I; Soejima K; Nishihara H; Fukunaga K Cancer Med; 2024 Feb; 13(4):e7077. PubMed ID: 38457233 [TBL] [Abstract][Full Text] [Related]
78. [A comparison of direct sequencing and ARMS assay performance in EGFR mutation analysis of non-small cell lung cancer patients]. Li C; Wu J; Wang Z; Feng J Zhongguo Fei Ai Za Zhi; 2014 Aug; 17(8):606-11. PubMed ID: 25130967 [TBL] [Abstract][Full Text] [Related]
79. Next generation sequencing for detection of Batra U; Nathany S; Sharma M; Jain P; Mehta A J Clin Pathol; 2022 Mar; 75(3):164-167. PubMed ID: 33372105 [TBL] [Abstract][Full Text] [Related]
80. An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Goto K; Satouchi M; Ishii G; Nishio K; Hagiwara K; Mitsudomi T; Whiteley J; Donald E; McCormack R; Todo T Ann Oncol; 2012 Nov; 23(11):2914-2919. PubMed ID: 22776705 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]